Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials

Clinical Therapeutics

Volumn 25, Issue 1, 2003, Pages 81-104

  Backonja, Miroslav ^a   Glanzman, Robert L ^b  

^a University of Wisconsin Health   (United States)

^b PFIZER INC   (United States)

Author keywords

Diabetic neuropathy; Gabapentin; Neuropathic pain; Neuropathic syndrome; Postherpetic neuralgia

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CAPSAICIN; CARBAMAZEPINE; DEXTROMETHORPHAN; GABAPENTIN; IBUPROFEN; LAMOTRIGINE; MEXILETINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PHENYTOIN; PLACEBO; STEROID; SULINDAC; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; ANALGESIA; ASTHENIA; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELDERLY CARE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERESTHESIA; KIDNEY FAILURE; LIVER FAILURE; MONOTHERAPY; NAUSEA; NEUROPATHIC PAIN; NEUROPATHOLOGY; OUTCOMES RESEARCH; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; QUESTIONNAIRE; RADICULOPATHY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPINAL CORD INJURY; STROKE; STRUCTURE ACTIVITY RELATION; SWEATING; UNITED KINGDOM; UNITED STATES; VERTIGO; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 0037274135     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90011-7     Document Type: Review

References (48)

1. Smith TE, Chong MS. Neuropathic pain. Hosp Med. 2000;61:760-766.
2. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
3. Clark MR, Heinberg LJ, Haythornthwaite JA, et al. Psychiatric symptoms and distress differ between patients with postherpetic neuralgia and peripheral vestibular disease. J Psychomat Res. 2000;48:51-57.
4. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
5. Haythornthwaite JA, Benrud-Larson LM. Psychological assessment and treatment of patients with neuropathic pain. Curr Pain Headache Rep. 2001;5:124-129.
6. Johnson RW. Herpes zoster and postherpetic neuralgia. Optimal treatment. Drugs Aging. 1997;10:80-94.
7. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997;73:123-139.
8. Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: An update. Drugs. 2000;59:1113-1126.
9. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in post-herpetic neuralgia: A single-dose study of clonidine, codeine, ibuprofen and placebo. Clin Pharmacol Ther. 1988;43:363-371.
10. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11-23.
11. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
12. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain. 1999;83:85-90.
13. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
14. Wallace MS. Pharmacologic treatment of neuropathic pain. Curr Pain Headache Rep. 2001;5:138-150.
15. Watson CP. The treatment of neuropathic pain: Antidepressants and opioids. Clin J Pain. 2000;16(Suppl 2):S49-S55.
16. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68:217-227.
17. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am J Med. 2000;108:2-8.
18. Backonja M. Anticonvulsants and antiarrhythmics in the treatment of neuropathic pain syndromes. In: Hansson PT, Fields HL, Hill RG, Marchettini P, eds. Neuropathic Pain: Pathophysiology and Treatment. Seattle, Wash: IASP Press; 2001:185-201.
19. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial. Pain. 1999;83:105-107.
20. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology. 2001;57:505-509.
21. Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: A randomized controlled trial. Neurology. 2001;56:184-190.
22. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: Results from a double-blind placebo controlled crossover trial. Pain. 1997;73:223-230.
23. Simpson DM, Olney R, MacArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-2119.
24. Neurontin [package insert]. New York: Pfizer Inc; 2002.
25. NDC Health - Retail Pharmaceutical Database. Unique projected patient counts from January 1998 through September 2000. Based on monthly reports to Pfizer Inc.
26. Gee NS, Brown JP Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768-5776.
27. Field MJ, Hughes J, Singh L. Further evidence for the role of the alpha(2)delta sub-unit of voltage dependent calcium channels in models of neuropathic pain. Br J Pharmacol. 2000;131:282-286.
28. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233-249.
29. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 2000;101:359-371.
30. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia. 1999;40(Suppl 9):S7-S13.
31. Gidal BE, Radulovic LL, Kruger S, et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40:123-127.
32. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46:409-427.
33. Boyd RA, Turck D, Abel RB, et al. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40:474-479.
34. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: What improvements are needed? Neurology. 2000;55(Suppl 3):S11-S16.
35. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56-58.
36. Stacey BR, Tipton KD, Owen GT, et al. Gabapentin and neuropathic pain states: A case series report. Reg Anesth. 1996;21(Suppl):65. Abstract.
37. Bennett GJ. Neuropathic pain: New insights, new interventions. Hosp Pract (Off Ed). 1998;33:95-114.
38. Xiao WH, Bennett GI. Gabapentin relieves abnormal pains in a rat model of painful peripheral neuropathy. Soc Neurosci Abstr. 1995;21:897. Abstract 356.17.
39. Shimoyama N, Shimoyama M, Davis AM, et al. Spinal gabapentin is antinociceptive in the rat formalin test. Neurosci Lett. 1997;222:65-67.
40. Rosenberg JM, Harrell O, Ristic H, et al. The effect of gabapentin on neuropathic pain. Clin J Pain. 1997;13:251-255.
41. Merren MD. Gabapentin for treatment of pain and tremor: A large case series. South Med J. 1998;91:739-744.
42. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA. 1998;280:1831-1836.
43. Serpell M. Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.
44. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837-1842.
45. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain. 2001;94:215-224.
46. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197.
47. Ware JJ, Snow KK, Kominski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
48. McNair D, Lorr M, Droppleman LF. Profile of Mood States: Manual. San Diego, Calif: Educational and Industrial Testing Service; 1981.